Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers
Parloop Bhatt, Vishva Patel, Prachi Shah, Keyur Parikh
doi:10.1101/2021.08.02.21260750
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus responsible for the ongoing Covid-19 pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine(HCQ) could prevent SARS CoV-2 in healthcare workers(HCW) at high-risk of exposure. Method: This voluntary observational study for the prevention and treatment of COVID-19 was conducted at a tertiary care center, from 12 th June to 12th October 2020(total 16 weeks). All consented asymptomatic HCW's of CIMS hospital were administered 400 mg HCQ twice a day on day one followed by 400 mg once weekly to be taken with meals up to 16 weeks. Data collected included OPD registration, risk assessment, medical and family history (related to COVID), physical examination and vitals, pulse oximetry, ECG (pre and post HCQ), drug adherence, side effects, adverse drug reactions.
Result: The study enrolled 927 full-time, hospital-based HCWs ((including doctors, nurses, paramedical, lab technicians, sanitary workers and others), of whom 731(78.85%) initially started HCQ while 196 (21.14%) did not volunteer. The median age and weight of the study population was 27.5 years and 69.5 kg respectively. No major associated co-morbidities were present in these HCW's. There was an increased trend towards non adherence to HCQ with each proceeding week more so after week 11. Of the 731 HCW's taking HCQ a total of 167(22.8%) tested COVID positive at different intervals of time as against 30 HCW (15.3%) out of 196 not taking HCQ. The rate of COVID-19 positive was statistically significantly higher in the HCW's taking HCQ (p=0.0220; 95% CI: 1.14% to 12.94%), as compared to those not on HCQ. Thus HCQ was not prophylactically effective against COVID 19 infection. No
References
Abella, Jolkovsky, Biney, Uspal, Hyman et al., None
Agrawal, Akhil, Goel, Gupta, Emerging prophylaxis strategies against COVID-19: Pulmonary medicine and critical care jodhpur, Monaldi Archives for Chest Disease,
doi:10.4081/monaldi.2020.1289Bi, Wu, Mei, Ye, Zou et al., Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study, Lancet Infect Dis,
doi:10.1016/S1473-3099(20)30287-5Bienvenu, Marty, Jones, Picot, Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020, One Health,
doi:10.1016/j.onehlt.2020.100141Erkan, Yazici, Peterson, Sammaritano, Lockshin, A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome, Rheumatology,
doi:10.1093/rheumatology/41.8.924Fda / Cder, Plaquenil ® Hydroxychloroquine Sulfate Tablets, Usp Description
Fiehn, Ness, Weseloh, Specker, Hadjiski et al., Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review, Z Rheumatol,
doi:10.1007/s00393-020-00785-4Gautret, Lagier, Parola, Van Thuan, Hoang et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Hellewell, Abbott, Gimma, Bosse, Jarvis et al., Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group
Li, Guan, Wu, Wang, Zhou et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med,
doi:10.1056/NEJMoa2001316Monti, Vertogen, Masini, Donati, Lilli et al., Hydroxychloroquine as Prophylaxis for COVID-19: A Review Front, Pharmacol,
doi:10.3389/fphar.2020.605185Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol,
doi:10.1038/s41584-020-0372-xSharma Ajay, Natasha, Taraneh, Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review, J Am Acad Dermatol,
doi:10.1016/j.jaad.2020.04.024Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing
Zhaoa, Linc, Rand, Musae, Yangf et al., Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak, Int J Infect Dis,
doi:10.1016/j.ijid.2020.01.050Zhu, Zhang, Li, Yang, Song et al., China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019, N Engl J Med,
doi:10.1056/NEJMoa2001017
